Hypergonadotropic Ovarian Failure Associated with an Inherited Mutation of Human Bone Morphogenetic Protein-15 (BMP15) Gene  by Di Pasquale, Elisa et al.
Am. J. Hum. Genet. 75:106–111, 2004
106
Report
Hypergonadotropic Ovarian Failure Associated with an Inherited Mutation
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Hypergonadotropic ovarian failure is a common cause of female infertility. It is a heterogeneous disorder that, in
the most severe forms, is a result of ovarian dysgenesis (OD). Most OD cases are associated with major X-
chromosome abnormalities, but the pathogenesis of this disorder is still largely undeﬁned in patients with a normal
karyotype. Animal models showed the important role in female reproduction played by the product of a gene
located at Xp11.2 in humans (BMP15). BMP15 is an oocyte-speciﬁc growth/differentiation factor that stimulates
folliculogenesis and granulosa cell (GC) growth. We report two sisters with a normal karyotype who are affected
with hypergonadotropic ovarian failure due to OD. The familial presentation suggested a genetic origin, and
candidate genes were screened for mutations. A heterozygous nonconservative substitution in the pro region of
BMP15 (Y235C) was identiﬁed in both sisters but not in 210 control alleles. This mutation was inherited from
the father. Mutant BMP15 appears to be processed abnormally, is associated with reduced GC growth, and an-
tagonizes the stimulatory activity of wild-type protein on GC proliferation. In conclusion, the ﬁrst natural mutation
in human BMP15 is associated with familial OD, indicating that the action of BMP15 is required for the progression
of human folliculogenesis. This condition represents an exceptional example of X-linked human disease exclusively
affecting heterozygous females who inherited the genetic alteration from the unaffected father. BMP15 defects are
involved in the pathogenesis of hypergonadotropic ovarian failure in humans.
Hypergonadotropic ovarian failure is a heterogeneous
disorder that, in the most severe forms, is a result of
ovarian dysgenesis (OD [MIM 233300]). OD accounts
for about half of the cases of primary amenorrhea
(Timmreck and Reindollar 2003). Most OD cases are
associated with major X chromosome abnormalities.Ac-
cordingly, genetic studies have identiﬁed several loci at
Xq and Xp11.2–p22.1 whose functions are relevant for
ovarian development (Zinn et al. 1998; Simpson and
Rajkovic 1999; Marozzi et al. 2000). The etiopatho-
genesis of this disorder is still largely undeﬁned in pa-
tients with a normal karyotype. Severe gonadotropin
receptor defects are, indeed, a rare cause of OD in 46,XX
women (Aittomaki et al. 1995; Layman et al. 1998),
suggesting the possible involvement of other candidate
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genes. Recently, animal models showed the important
role in ovarian development and folliculogenesis played
by the paracrine action of growth/differentiation factors
(GDF9 and GDF9b or BMP15) that originate from
oocyte cells (Dube et al. 1998; Galloway et al. 2000;
Yan et al. 2001; Hanrahan et al. 2004). BMP15 (MIM
300247), in particular, is the product of a gene located
at Xp11.2 in humans (Dube et al. 1998). Bmp15 knock-
out female mice are subfertile and show reduced ovu-
lation rates after gonadotropin treatment (Yan et al.
2001). Natural mutations in the Bmp15 gene in sheep,
termed “fecundity X Inverdale and Hanna” (FecXI/H),
have provided insight into the role of BMP15 in female
reproduction (Galloway et al. 2000). Ewes with hetero-
zygous mutations exhibited increased ovulation and
lambing rates, whereas severe infertility with an early
block in folliculogenesis was seen in ewes with homo-
zygous mutations. In humans, BMP15 transcripts could
be detected in gonads by RT-PCR. In situ hybridization
localized the transcript to the oocyte of developing fol-
licles (Aaltonen et al. 1999). BMP15 is a growth/differ-
entiation factor, a member of the transforming growth
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Figure 1 Pedigree and sequence analysis. A, Pedigree of the family. The elder sister (VB) and her younger sister (SB) were affected with
idiopathic hypergonadotropic ovarian failure and presented with primary amenorrhea. After a 3-mo estrogen withdrawal, estradiol was low
(!0.1 nmol/L) and gonadotropin values rose into the postmenopausal range, as shown (premenopausal female values: FSHp 1.0–8.0 U/L; LH
p 0.5–9.0 U/L). The mother had regular menses and was postmenopausal at the time of the study (physiological menopause at 49 years), and
the father had normal fertility and gonadal function (FSHp 5.3 U/L; LHp 2.5 U/L; testosteronep 15.6 nmol/L). B, BMP15 sequence analyses
in VB, SB, and the parents. In the proband (VB), automated sequencing revealed a heterozygous ArG transition at base pair 704 of the BMP15
gene located at Xp11.2. The same heterozygous transition was seen in the younger sister, whereas the father was a hemizygous carrier of the
same 704ArG transition and the mother was normal. The grandmother, two uncles, and two aunts of the paternal family had normal fertility
(ﬁve, one, one, four, and three births, respectively). One of these aunts had a normal BMP15 sequence; therefore, the mutation should have
arisen de novo in the hemizygous father. This transition generates a missense substitution (Y235C) located in the propeptide region of the
BMP15 protein.
factor-b (TGF-b) superfamily (Chang et al. 2002). Mem-
bers of this superfamily control many aspects of devel-
opment by binding and activating two types of trans-
membrane serine/threonine kinase receptors (Chang et
al. 2002). Functional studies have shown that BMP15
stimulates GC growth and promotes the progression of
folliculogenesis from the primary stage to the FSH-
dependent stage (Otsuka et al. 2000; Chang et al. 2002;
Shimasaki et al. 2004).
An Italian family with two female siblings affected
with hypergonadotropic ovarian failure (ﬁg. 1A) came
to our attention recently. At 23 years old, the proband
(VB) presented with primary amenorrhea and modest
hirsutism (Ferriman-Gallwey scorep 12 [Ferriman and
Gallwey 1961]; normal values are !8). She was born at
term after an uneventful pregnancy. Her physical and
intellectual development were fairly normal until pu-
berty. Owing to the lack of spontaneous menarche, the
diagnosis of pubertal delay was given when she was 15
years old, but no treatment was initiated. At age 17
years, she underwent appendectomy, and laparoscopic
investigation allowed the visualization of streak ovaries
with a small terminal crest and hypogenesia of the
uterus. She was put on estroprogestin therapy soon after
surgery. Family history revealed that her younger sister
(SB) was also affected with a similar menstrual defect,
reporting a single episode of spotting at 13 years. At the
time of this clinical evaluation, SB was 18 years old and
had been receiving estroprogestins for 18 mo. Both pa-
tients had hypoplasic gonads at ultrasound (ovarian di-
ameters !18 mm, with a homogeneous structure and
without visible follicles) and a 46,XX karyotype. Their
BMIs were 24 and 22 kg/m2, respectively, and all other
endocrine functions were normal. Anti-ovary autoanti-
bodies were negative on two occasions and there was
no evidence of other speciﬁc autoimmune disease. Fer-
tility and gonadal function were unaffected in both par-
ents. The parents of VB and SB were not consanguin-
eous, and clinical history of the family was negative for
reproductive, endocrine, or mental disorders in the two
previous generations.
We decided to screen candidate genes for OD in this
family. An institutional ethical committee approved the
study protocol, and informed consent and blood samples
for genetic investigations were obtained from all family
members.
The phenotype of these patients was similar to that
observed in patients with complete resistance to FSH
action (Aittomaki et al. 1995). Accordingly, we had ex-
cluded mutations in the FSH-receptor coding sequence
in the proband (see methods in appendix A [online
only]). Because of evidence in animal models, investi-
gations were focused on genes encoding for oocyte-spe-
ciﬁc growth/differentiation factors of the TGF-b super-
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Figure 2 Alignment of the amino acid sequence of part of the
BMP15 propeptide region from several mammalian species with its
human homologue GDF9. The tyrosine affected by the mutation and
the surrounding residues are highly conserved.
Figure 3 Western immunoblotting was performed under reducing and nonreducing conditions (with or without b-mercaptoetanol [b-
ME]) by use of anti-His-HRP antibody (Roche) or anti-Myc antibody (Invitrogen), as appropriate. Immunoﬂuorescent signals were detected
with the use of the ECL system (Amersham). Western blots performed with anti-Myc antibody are shown. A, Analysis performed in the presence
of b-ME. Bands corresponding to mature (duplet at ∼21–23 kDa) and precursor (at ∼50–55 kDa) BMP15-Myc-His chimeras were seen in the
WT and mutant (MUT) lanes but were not seen in the control media from nontransfected (NT) cells. B, Analysis performed under nonreducing
conditions allowing the visualization of dimeric products. Bands corresponding to mature (∼45 kDa) and precursor (1110 kDa) dimers were
seen in both WT and MUT lanes. Additional bands corresponding to precursor monomers (∼50–55 kDa) or to stable precursor-mature dimers
(∼80 kDa) were detected in the mutant Y235C-BMP15 but not in WT lanes, even when double the amount of protein was tested (WT 2x).
The band at 65–70 kDa in both panels corresponds to a nonspeciﬁc cross-reacting protein present in all media.
family (Chang et al. 2002; Shimasaki et al. 2004). A
Japanese group (Takebayashi et al. 2000) reported the
absence of BMP15 and GDF9 mutations in women with
postpubertal onset of hypergonadotropic ovarian failure
and secondary amenorrhoea or with polycystic ovaries.
In the two sisters, the GDF9 coding sequence (GenBank
accession number NM_005260) was completely nor-
mal, but we found a heterozygous ArG transition at
base pair 704 of the BMP15 gene (GenBank accession
number AF082349) in the constitutive DNA of VB (ﬁg.
1B; see methods in appendix A [online only]). The same
heterozygous transition was seen in SB, whereas the fa-
ther was a hemizygous carrier of the same transition,
and the wild-type BMP15 coding sequence was seen in
the mother. This transition does not represent a poly-
morphic variant diffuse in the white population, as it
was absent in a series of 210 alleles from 120 ethnically
matched controls (90 women and 30 men). Thus, this
heterozygous transition of the BMP15 gene leads to a
Y235C mutation associated with prepubertal onset of
hypergonadotropic ovarian failure characterized by pri-
mary amenorrhea and ovarian hypoplasia. These man-
ifestations reﬂect the phenotype of sheep with homo-
zygous mutations, rather than that of heterozygous ewes
(Galloway et al. 2000; Hanrahan et al. 2004). The pos-
sibility that the affected sisters inherited additional al-
terations in other genes involved in ovarian functionmay
explain such discrepancy. Nevertheless, mutations in
GDF9 and FSHR genes were not detected, possibly sug-
gesting that the different modes of inheritance in humans
and sheep may be a result of species diversity or the
peculiar nature and location of the human mutation.
The missense mutation lies in the second exon, in a
highly conserved part of the BMP15 gene encoding the
propeptide region (ﬁg. 2). The pro region plays impor-
tant biological roles, with a signiﬁcant impact on secre-
tion and action of TGF-b superfamily members (Chang
et al. 2002). All TGF-bs are, indeed, synthesized as pre-
propeptide precursors (comprising the signal peptide,
pro region, and bioactive mature domain) (Chang et al.
2002). The processing of TGF-b precursors is a critical
step that modulates the availability of bioactive peptides
at the target tissue level. Accordingly, TGF-bs are se-
creted partially as latent forms, and the pro region is
cleaved by speciﬁc proteases in the intracellular or ex-
tracellular compartments as an important component of
the posttranslational processing that leads to the release
of the bioactive mature peptides (Gentry et al. 1988;
Schultz-Cherry et al. 1994; Saharinen et al. 1999; Chang
et al. 2002; Liao et al. 2003). Moreover, the pro region
is involved in dimerization, and an essential role in this
process was assigned to three Cys residues in the pro
region of TGF-b1 (Brunner et al. 1989). The wild-type
(WT) BMP15 lacks these characteristic cysteines. On the
basis of all this data, the replacement of the highly con-
served Tyr235 with a Cys was predicted to cause relevant
modiﬁcations in the conformation of the BMP15 precur-
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Figure 4 Granulosa cell-growth assay evaluated by direct cell
count (see methods in appendix A [online only]). Results (mean 
SD) of a representative assay using different doses of BMP15-Myc-
His fusion proteins. Tagged proteins were puriﬁed on nickel columns,
and doses of puriﬁed proteins (0.1 or 0.2 mg/ml) were tested in triplicate
wells. An asterisk (*) indicates versus control and mutant prep-P ! .05
arations (two-tailed, unpaired Student’s t test).
sor, possibly leading to altered processing and impaired
activation of latent forms or to abnormal dimerization.
For functional studies, stable clones of human em-
bryonic kidney 293T (HEK293T) cells expressing WT
BMP15 or Y235C mutant BMP15 were obtained (see
methods in appendix A [online only]). Western blotting
qualitatively investigated immunoprecipitated BMP15
forms secreted by HEK293T cells. Under reducing con-
ditions (ﬁg. 3A), bands corresponding to mature and
precursor BMP15-Myc-His chimeras were seen in the
WT and mutant lanes, indicating that signiﬁcant
amounts of processed or unprocessed fusion proteins
were secreted into the culture media in both cases. Under
nonreducing conditions (ﬁg. 3B), bands corresponding
to mature and precursor dimers were seen in the WT
and mutant lanes, but additional bands corresponding
to precursor monomers or to stable precursor-mature
dimers were visible only in the mutant lane, even when
a double amount of WT protein was tested. These fea-
tures are consistent with an altered processing of the
Y235C mutant. The introduction of the Cys into the
BMP15 pro region may confer to the mutant precursor
the ability to form covalent heterodimers with mature
peptides through the formation of abnormal disulﬁde
bonds. The biological impact of the Y235C mutation is
demonstrated with GC growth assays (Tapanainen et al.
1987) (appendix A [online only]). Human GCs were
obtained by centrifugation of follicular ﬂuids after the
oocyte pick-up procedure in women undergoing in vitro
fertilization. The women gave their informed consent.
Cell count showed that GCs proliferated in the absence
of recombinant BMP15 constructs (control cell countp
143% of basal). The proliferation rate of GCs was stim-
ulated by the addition of WT (79% or 113% of
control values of 0.1 or 0.2 mg/ml, respectively), whereas
no signiﬁcant variation was seen in the presence of both
doses of mutant (ﬁg. 4). Accordingly, WT-BMP15 sig-
niﬁcantly stimulated 3H-thymidine incorporation in
GCs, with a dose-response effect between 0.1 and 0.5
mg/ml (ﬁg. 5A). In contrast, GC growth was not stim-
ulated in the presence of increasing Y235C-BMP15
doses or when GCs were incubated with equal amounts
(1:1) of WT and mutant proteins. A signiﬁcant increase
of 3H-thymidine incorporation in GCs was restored in
the presence of WT-BMP15 concentrations 5-fold higher
than those of Y235C-BMP15 (5:1). Despite heteroge-
neity among diverse GC preparations with variable basal
growth rates, reciprocal differences between different
BMP15 preparations were conserved in eight distinct
experiments (ﬁg. 5B).
In summary, these experiments showed that WT-
BMP15 stimulates human GC growth in a dose-depen-
dent manner and that Y235C-BMP15 products lost
stimulatory activity. When equal amounts of WT and
mutant BMP15 preparations were coincubated with
GCs, the abolition of WT stimulatory action was seen.
Therefore, Y235C-BMP15 appears to generate a dom-
inant negative effect on WT-BMP15 action. The for-
mation of abnormal dimers producing a potent domi-
nant negative effect by preventing the secretion of
bioactive proteins was reported elsewhere in the case of
the C400Y mutation of a BMP-like protein, the carti-
lage-derived morphogenetic protein-1 in an autosomal
dominant form of chondrodysplasia (Thomas et al.
1997). Similarly, BMP15 mutations in sheep (Galloway
et al. 2000) were reported to impair intracellular pro-
cessing and the secretion of bioactive peptides (Liao et
al. 2003). The dominant negative effect exerted by
Y235C-BMP15 may be explained by means of two dif-
ferent molecular mechanisms: (1) impaired pro-protein
processing and reduced production of bioactive peptides
and (2) secretion of unprocessed monomer or dimeric
mutant products with an antagonistic effect on GCs at
the target level. The relevance of the latter mechanism
was conﬁrmed by GC proliferation assay through the
abrogation of WT-BMP15 growth effect when WT pro-
tein was coincubated with equal amounts of mutant.
Though speciﬁc BMP15 receptors are still not deﬁned,
binding to two distinct receptor types on GCmembranes
is expected for the generation of BMP15 signal (Chang
et al. 2002; Moore et al. 2003). It is conceivable that
Y235C-BMP15 unprocessed products (either monomer
or abnormal dimer) may interact with one of the two
receptor isoforms required for signal transduction in
GCs, thus limiting receptor availability for WT-BMP15
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Figure 5 Granulosa cell-growth assay evaluated by 3H-thymi-
dine incorporation (see methods in appendix A [online only]). A, Re-
sults (mean  SD) of a representative assay using different doses of
BMP15-Myc-His fusion proteins. Tagged proteins were obtained after
afﬁnity chromatography on nickel columns. Mutant BMP15 and WT-
BMP15 were tested either separately or in combination (1:1 or 1:5
mixtures) in triplicate wells. An asterisk (*) indicates versusP ! .01
control and mutant alone; a double dagger (‡) indicates versusP ! .02
WT 0.1 mg/ml; a dagger (†) indicates versus WT 0.2 mg/ml;P ! .03
and two asterisks (**) indicate versus control andmutant aloneP ! .03
(two-tailed, unpaired Student’s t test). B, Effects of recombinant hu-
man BMP15 tagged proteins (0.2 mg/ml) on GC growth, tested in eight
experiments with the use of different GC preparations from eight
women undergoing ovarian hyperstimulation. Owing to variable
growth rates among these different GC preparations, results (mean
SE; ) obtained with WT, mutant, or 1:1 mixtures are expressednp 8
as the percentage of 3H-thymidine incorporation in control wells. In
WT-BMP15 wells, growth rate was 165%  6% (mean  SE) of
control wells ( ). In contrast, growth rates were reduced sig-P ! .001
niﬁcantly, by 12-fold, when mutant BMP15 was tested separately or
in the presence of equal amounts (1:1) of WT (74%  4% or 69%
 6% of controls, respectively). An asterisk (*) indicates P ! .001
versus WT-BMP15 (two-tailed, unpaired Student’s t test).
action and creating a functional antagonism. Consis-
tently, the antagonism exerted by mutant products can
be overcome partially by the addition of 5-fold higher
WT-BMP15 concentrations. A similar mechanism was
described to modulate the activity of another member
of the TGF-b superfamily, that is, the antagonism on
activin function generated by inhibin binding to beta-
glycan (Lewis et al. 2000). Although evidence in animal
models (Galloway et al. 2000; Hanrahan et al. 2004)
suggests that additional genetic alterations may be re-
quired to generate the clinical phenotype of our patients,
the present experimental ﬁndings indicate that Y235C-
BMP15 could antagonize the activity ofWT protein. The
biological relevance in vivo of the partial processing de-
fect may also develop from the peculiar type of BMP15
paracrine action in the restricted follicle compartment.
In conclusion, the diminished GC proliferation ob-
served in vitro in the presence of Y235C-BMP15 can
explain the in vivo phenotype of primary amenorrhoea
and hypoplasic ovaries in the two 46,XX sisters with
the BMP15 mutation. The hemizygous father was ap-
parently unaffected. Extragonadal tissues known to ex-
press BMP15 include the pituitary (Otsuka and Shi-
masaki 2002), but normal gonadotropin secretion in the
father argues against an essential role for BMP15 at this
level. Our data indicate that mutations in BMP15 gene
can be associated with hypergonadotropic ovarian fail-
ure in humans and that BMP15 is one of the factors
whose function is relevant for OD in Turner syndrome.
Owing to the essential role, limited to the female sex,
of the growth/differentiation pathway affected by
BMP15 mutation (Dube et al. 1998; Aaltonen et al.
1999; Galloway et al. 2000; Otsuka et al. 2000; Yan et
al. 2001; Chang et al. 2002; Hanrahan et al. 2004; Shi-
masaki et al. 2004), this condition represents an excep-
tional example of X-linked human disease exclusively
affecting heterozygous females who inherited the genetic
alteration from their unaffected fathers.
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